Mesa Laboratories (MLAB) CAO Elizabeth Sells $12K of Stock

Crennen Lyndsey Elizabeth, the Chief Accounting Officer of Mesa Laboratories, Inc. (NasdaqGS: MLAB), sold 118 shares in a planned transaction on June 16, 2026. The shares were sold at an average price of $101.27, totaling $11,949.86.

Insider Buying and Selling at Mesa Laboratories, Inc.

In addition to Crennen Lyndsey Elizabeth, other insiders also made transactions on June 16, 2026. John Sakys, the company's CFO, sold 1,223 shares at the same price, while Brian David Archbold, Senior Vice President of Operations, sold 1,151 shares. On June 15, 2026, Sakys purchased 2,717 shares at $104.08, and Archbold acquired 4,328 shares, though the exact price wasn't disclosed.

Other Institutional Activity in Mesa Laboratories

Several institutional investors also adjusted their positions in Mesa Laboratories. Long Path Partners LP significantly increased its holdings by 178,360 shares, bringing its total to 405,583 shares valued at approximately $35.86 million. BlackRock, Inc. slightly reduced its position by 4,815 shares, ending with 393,851 shares worth $34.82 million. Boston Partners added 55,335 shares, now holding 268,711 shares valued at $23.76 million. Select Equity Group, L.P. increased its stake by 29,450 shares to a total of 235,885 shares valued at $20.86 million. Meanwhile, Ranger Investment Management, L.P. trimmed its position by 2,360 shares, holding 202,903 shares worth $17.94 million.

Mesa Laboratories, Inc. Stock Down 25.0%

Shares of Mesa Laboratories (NasdaqGS: MLAB) traded near $99.68. The company has a market capitalization of approximately $550.7 million, with a P/E ratio of 82.38 and a forward P/E of 8.12. The stock's beta is 0.927, indicating lower volatility compared to the broader market. Over the past year, the stock has ranged from a low of $55.45 to a high of $113.99. Its 50-day moving average is $101.95, and the 200-day moving average is $84.68. The company's current ratio is 1.717, with a quick ratio of 1.174 and a debt-to-equity ratio of 90.65.

Recent Earnings

Mesa Laboratories reported revenue of $249.13 million with a modest growth rate of 2.6%. The net margin was 2.694%, and the return on equity stood at 3.879%. Earnings per share were $1.21. The next earnings report is scheduled for August 5, 2026.

Dividend

Mesa Laboratories offers an annual dividend rate of $0.64, providing a yield of 0.64%. The dividend payout ratio is 52.89%.

Analysts Set New Price Targets

Wells Fargo maintained a "hold" rating on February 4, 2026, with a price target of $94.0. The consensus among analysts is a "hold" rating, with a mean target price of $112.0 based on 2 analyst opinions.

About Mesa Laboratories

Mesa Laboratories, Inc., headquartered in Lakewood, Colorado, develops and sells life sciences tools and quality control products. Operating across North America, Europe, and the Asia Pacific, it serves industries like pharmaceuticals and healthcare. The company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Led by CEO Dr. Siddhartha Chandrakant Kadia, Mesa Labs employs 717 people.

Bottom Line

This insider sale is part of a planned transaction, reflecting routine activity rather than a strategic shift. Investors often keep an eye on such insider moves for potential insights. It's important to remember that 13F filings and insider transactions are historical data and may not represent current positions.